Julius Knowles - Jun 4, 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 04:15 PM
Previous filing
Jun 3, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Knowles Julius Director C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Keith Regnante, Attorney-in-Fact 2025-06-06 0001808365

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Award $0 +5.25K +440.81% $0.00 6.44K Jun 4, 2025 Direct F1
holding KROS Common Stock 342K Jun 4, 2025 See footnote F2
holding KROS Common Stock 233K Jun 4, 2025 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (right to buy) Award $0 +10.5K $0.00 10.5K Jun 4, 2025 Common Stock 10.5K $14.82 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
F2 The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F3 The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
F4 The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.